| Market revenue in 2025 | USD 440.7 million |
| Market revenue in 2033 | USD 859.5 million |
| Growth rate | 8.8% (CAGR from 2026 to 2033) |
| Largest segment | Mrna reprogramming |
| Fastest growing segment | MRNA Reprogramming |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Sendai Virus-based Reprogramming, MRNA Reprogramming, Episomal Reprogramming |
No credit card required*
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| FUJIFILM Holdings Corp | View profile | 83,784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | www.fujifilmholdings.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Bio-Techne Corp | View profile | 3,050 | 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 | www.bio-techne.com |
| Astellas Pharma Inc | View profile | 14,484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | www.astellas.com |
| ReproCELL | View profile | 51-100 | Yokohama, Kanagawa, Japan, Asia | reprocell.com |
| STEMCELL Technologies | View profile | 501-1000 | Vancouver, British Columbia, Canada, North America | www.stemcell.com |
| Allele Biotech | View profile | 11-50 | San Diego, California, United States, North America | www.allelebiotech.com/ |
| Alstem | View profile | 11-50 | Richmond, Virginia, United States, North America | www.alstembio.com/web/ |
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell Reprogramming Market Outlook will help companies and investors design strategic landscapes.
Mrna Reprogramming was the largest segment with a revenue share of 35.35% in 2025.
Horizon Databook has segmented the Global cell reprogramming market based on sendai virus-based reprogramming, mrna reprogramming, episomal reprogramming covering the revenue growth of each sub-segment from 2021 to 2033.
Horizon Databook provides a detailed overview of global-level data and insights on the Global Cell Reprogramming Market Outlook, including forecasts for subscribers. This global databook contains high-level insights into Global Cell Reprogramming Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
